Cordis Showcases Cardiovascular Innovations at EuroPCR 2013
Cordis Showcases Cardiovascular Innovations at EuroPCR 2013
FREMONT, Calif.--(BUSINESS WIRE)-- Cordis Corporation, a global leader in innovative technology for cardiovascular interventions, will introduce the two latest additions to its portfolio of cardiovascular solutions at EuroPCR 2013, 21-24 May in Paris. EuroPCR is Europe's largest meeting for interventional cardiovascular medicine.
"We are excited to meet with our physician colleagues from around the world and demonstrate our commitment to them and to their patients," said Shlomi Nachman, Worldwide President, Cordis Corporation. In addition to introducing its newest technology, Cordis will offer attendees demonstrations, opportunities for hands-on experiences and a glimpse at advances to come.
Among the highlights Cordis will unveil for meeting attendees are:
S.M.A.R.T.® Flex Vascular Stent System*
Designed to be fully connected and yet flexible, the S.M.A.R.T.® Flex Vascular Stent System represents the latest innovation in self-expanding stents. It is engineered to optimize flexibility, fracture resistance and radial strength with predictable placement. Acquired by Cordis in March 2013, the S.M.A.R.T.® Flex Vascular Stent System represents an extension of the Cordis S.M.A.R.T.® Stent platform to address unmet needs in the treatment of peripheral arterial disease and expand the company's therapeutic applications.
EuroPCR attendees can experience the S.M.A.R.T.® Flex Vascular Stent System in the new EuroPCR Peripheral Village as well as in the Cordis booth.
ADROIT™ Guiding Catheter
Cordis will launch its latest innovation in guiding catheters: the ADROIT™ 6F Guiding Catheter**. The ADROITTM Guiding Catheter incorporates important technological advances. The catheter has been engineered to accommodate easier advancement of devices with its 0.072' diameter, the largest inner diameter of any 6F guiding catheter on the market, while maintaining excellent support and control. These features offer physicians more options for treating a wide range of challenging cases, including the treatment of complex lesions and cases using the radial approach.
The ADROITTM Guiding Catheter received European CE Mark approval on 17 May.
Attendees can get a firsthand look at this latest innovation in guiding catheter technology at the Cordis booth. "ADROIT™: The Innovation and Technology" sessions will repeat daily, enabling attendees to meet the experts and see demonstrations.
Cordis-Sponsored Symposium on Renal Denervation***
Reflecting its continual pursuit of innovation to improve treatment options and patient outcomes, Cordis will sponsor a EuroPCR Symposium: "Advancing Innovations in Catheter-Based Renal Sympathetic Denervation" on Wednesday 22 May, 2013, 12.00 pm.
Cordis Cardiac & Vascular Institute
Throughout the Congress, the Cordis Cardiac & Vascular Institute will offer dedicated educational and hands-on sessions in the Cordis Learning Centre located in the EuroPCR Training Village. Repeating sessions include:
- Radial approach for coronary diagnostic and interventions - hands-on with the experts
- Femoral artery access and hemostasis
- Advanced tips and tricks: vessel preparation and post dilation
- Endovascular complication management: renal access
Cordis offers comprehensive training through the Cardiac & Vascular Institute programme, conducted in co-operation with leading interventional cardiologists, who have the goal of sharing expertise for better patient outcomes.
About Cordis Corporation
Cordis Corporation, part of the Johnson & Johnson Family of Companies, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with physicians worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com (this site is intended for U.S. visitors).
*The S.M.A.R.T.® Flex Vascular Stent System received European CE Mark approval for the treatment of vascular disease (iliac, SFA and popliteal) in January 2009. In the U.S., the S.M.A.R.T.® Flex Biliary Stent System received 510(k) clearance from the Food and Drug Administration (FDA) solely for the palliative treatment of biliary strictures associated with malignant tumors in September 2009; peripheral vascular indications are investigational in the United States.
**The ADROIT™ Catheter is not approved/cleared for use or available in the United States.
***This event has been made possible by an educational sponsorship from Cordis and is intended for Healthcare Professionals only.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Cordis Corporation and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Cordis Corp. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)
For Cordis Corporation
Sandy Pound, (m) 908-432-2829
KEYWORDS: United States North America California New Jersey
The article Cordis Showcases Cardiovascular Innovations at EuroPCR 2013 originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.